675126-26-8

Basic information

• Product Name: 2-Amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile
• Synonyms: 2-Amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile;4-methoxy-5-(3-morpholinopropoxy)-2-nitrobenzonitrile;2-Nitro-4-Methoxy-5-(3-Morpholinopropoxy)benzonitrile;4-Methoxy-2-nitro-5-(3-Morpholinopropoxy)benzonitrile;4-Methoxy-5-(3-Morpholinopropoxy)-2-Nitrobenzonitrile Gefitinib HCL InterMediates G4;Benzonitrile,4-Methoxy-5-[3-(4-Morpholinyl)propoxy]-2-nitro-;Gefitinib PI-1;-nitro-4-methoxy-5-(3-morpholinopropoxy)benzonitrile
• CAS NO: 675126-26-8
• Molecular Formula: C₁₅H₁₉N₃O₅
• Molecular Weight: 291.34554
• EINECS: 1806241-263-5
• Mol File: 675126-26-8.mol
• Article Data: 13

Chemical Properties

• Melting Point: 127℃
• Boiling Point: 522.302 °C at 760 mmHg
• Flash Point: 269.679 °C
• Appearance: /
• Density: 1.29
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 6.96±0.10(Predicted)
• CAS DataBase Reference: 2-Amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile(675126-26-8)
• EPA Substance Registry System: 2-Amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile(675126-26-8)

Safety Data

• Hazardous Substances Data: 675126-26-8(Hazardous Substances Data)

Usage

General Description

"2-Amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile" is a specific chemical compound that belongs to the class of organic compounds. This organic compound belongs to the family of benzonitriles, which are aromatic compounds containing a benzenoid ring with a cyano group attached to it. Yet it also consists of a methoxy group, an amino group, and a morpholinopropoxy group which are directly attached to the benzene ring. Currently, there's limited data about its specific chemical properties, toxicity, biological activities, and practical applications. More comprehensive studies and research are required to understand it in depth.

Upstream product

• 861453-13-6 4-methoxy-6-nitro-3-[3-(4-morpholinyl)propoxy]benzaldoxime 
• 929683-54-5 3-(3-chloropropoxy)-4-methoxybenzaldehyde 
• 110-91-8 morpholine 
• 1315512-61-8 C₁₁H₁₁ClN₂O₄ 
• 7357-67-7 4-(3-chloropropyl)morpholine 
• 102714-71-6 4,5-dimethoxy-2-nitrobenzonitrile 
• 861453-11-4 4-methoxy-3-[3-(4-morpholinyl)propoxy]benzaldehyde 
• 934191-95-4 4-methoxy-3-[3-(4-morpholinyl)propoxy]benzaldoxime 
• 621-59-0 isovanillin 
• 675126-28-0 4-methoxy-3-[3-(morpholin-4-yl)propoxy]benzonitrile 
• 52805-46-6 2-methoxy-5-cyanophenol 

Downstream Products

• 184475-35-2 gefitinib 
• 861453-16-9 2-nitro-4-methoxy-5-[3-(morpholin-4-yl)propoxy]benzamide 
• 199327-59-8 4-chloro-7-methoxy-6-(3-morpholinopropoxy)quinazoline 
• 246512-44-7 2-amino-4-methoxy-5-[3-(morpholin-4-yl)propoxy]benzamide 
• 847949-49-9 O-Demethyl-Gefitinib 
• 199327-61-2 7-methoxy-6-(3-morpholinopropoxy)-3,4-dihydroquinazolin-4-one 
• 675126-27-9 2-amino-4-methoxy-5-[(3-morpholin-4-yl)propoxy]benzonitrile 

Relevant articles and documents

4-heterocycle substituted quinazoline derivative and preparation method and application thereof

The invention discloses a 4-heterocycle substituted quinazoline derivative and a preparation method and application thereof. The compound has a structure expressed by a general formula (I): (please see the specification for the formula), in the formula, R1 and R2 are independently selected from hydrogen, a saturated or unsaturated five-membered heterocycle, or a saturated or unsaturated six-membered heterocycle, and n is an integer from 1 to 6; X is NH, O or S; and a heterocycle A is independently selected from pyridine or substituted pyridine, pyrimidine or substituted pyrimidine, pyrazol orsubstituted pyrazol, pyrazine or substituted pyrazine, thiazole or substituted thiazole, or benzothiazole or substituted benzothiazole. The compound or pharmaceutically formable salts thereof have aninhibitory effect on proliferation of tumor cells and can be used for preparing drugs for treatment of glioma, non-small cell lung cancer, breast cancer, colon cancer, stomach cancer, liver cancer andcervical cancer diseases.

Preparing method of gefitinib intermediate

The invention discloses a preparing method of a gefitinib intermediate. The method includes the following steps of firstly, making a compound 1 react in the presence of sodium formate, formic acid andhydroxylamine sulphate to obtain a compound 2; secondly, making the compound 2 and a compound 3 react in the presence of potassium carbonate in a first solvent to obtain a compound 4; thirdly, makingthe compound 4 react in the presence of sulfuric acid and nitric acid in a second solvent to obtain a compound 5; fourthly, making the compound 5 react in the presence of alkaline and hydrogen peroxide in a third solvent to obtain a compound 6; fifthly, making the compound 6 react in the presence of ammonium formate and palladium/carbon in a fourth solvent to obtain a compound 7; sixthly, makingthe compound 7 react in the presence of formic acid and formamide to obtain a compound 8.

Efficient preparation method of gefitinib

The invention provides an efficient preparation method of gefitinib. 2-nitro-4,5-dimethoxybenzonitrile is used as a starting material and subjected to a demethylation reaction, a substitution reaction, a nitro reduction reaction, a ring forming reaction, an amino substitution reaction and the like to obtain a finished gefitinib product. By means of the preparation method, gefitinib with the purityhigher than 99.9% can be obtained, the total yield of the preparation method is 61-75%, raw materials used in the method are low in price, there are only five steps in the process route, the operation is simple and easy to control, the yield of the target product is high, and the repeatability is good.